Patients and clinicians who have questions like, “What is the best injection for osteoporosis?” are usually met with a crowded field of antiresorptive and anabolic drugs, each with a different mechanism, dosing schedule, and risk profile. Determining the best treatment for osteoporosis often comes down to matching a patient’s fracture risk, prior treatment history, and tolerance for side effects to the right drug class.
Medica Depot compiles reference material on the osteoporosis injection category for licensed professionals who buy osteoporosis injection products for their practice, and this guide sets out a straightforward comparison of the injectable options currently used in clinical care.
This article explores how selective estrogen receptor modulators, bisphosphonates, RANKL inhibitors, and anabolic agents compare in efficacy, safety, cost, and long-term suitability, so professionals can better understand where each option fits in a treatment plan.
Key Takeaways
- No single injection is universally “best.” Antiresorptive drugs such as bisphosphonates and denosumab slow bone loss, while anabolic drugs such as teriparatide, abaloparatide, and romosozumab actively build new bone. The right choice depends on fracture risk and prior treatment history.
- Denosumab and romosozumab have shown some of the strongest vertebral fracture risk reductions in clinical trials, but each carries distinct rebound and cardiovascular considerations, respectively.
- Cost and dosing frequency vary widely, from low-cost generic bisphosphonates to biologic agents costing tens of thousands of dollars annually, which meaningfully affects long-term adherence.
About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. We offer a worry-free experience in searching for the best and most popular products on the market, like osteoporosis injections. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.
What Are the Main Injection Options for Osteoporosis?
Medication for osteoporosis generally falls into two functional categories. Antiresorptive agents slow the rate at which old bone is broken down, while anabolic agents stimulate the formation of new bone.
Bisphosphonates and the RANKL inhibitor denosumab are the most widely prescribed antiresorptive injections. Teriparatide, abaloparatide, and romosozumab represent the anabolic and dual-action side of the field.
Selective estrogen receptor modulators are also part of the broader medication landscape for treating osteoporosis, though, as covered below, they do not fit neatly into the injection category.
For people with osteoporosis at high fracture risk, guidelines increasingly favor starting with an anabolic agent before transitioning to an antiresorptive drug to preserve the bone gains, rather than defaulting to bisphosphonates in every case.
How Do Selective Estrogen Receptor Modulators Work as Osteoporosis Injections?
Selective estrogen receptor modulators (SERMs), with raloxifene as the primary example used in osteoporosis care, mimic estrogen’s protective effect on bone while blocking estrogen activity in tissues such as the breast and uterus.
For accuracy, raloxifene is administered as a daily oral tablet rather than an injection, which sets it apart from every other option in this comparison. It is included because it remains a relevant point of reference when postmenopausal patients weigh the full range of pharmacologic choices, including injectable options.[3]
Raloxifene has demonstrated reductions in vertebral fracture risk, but the evidence for reducing hip and other non-spine fractures is weaker than for several injectable options. The main safety consideration is an increased risk of blood clots, including deep vein thrombosis and pulmonary embolism, which generally rules SERMs out for patients with a personal history of venous thromboembolism (VTE) or other strong risk factors.[4]
How to Manage Long-Term Bisphosphonate Therapy
Bisphosphonates remain the most commonly prescribed class for treating osteoporosis. They are available as oral tablets (alendronate, risedronate) and as injectable or infused formulations, most notably intravenous zoledronic acid, dosed as infrequently as once yearly. They bind to bone mineral and inhibit the osteoclasts responsible for bone resorption.
The long-term use of bisphosphonates is generally well tolerated, though rare cases have been associated with atypical femoral fractures and osteonecrosis of the jaw after several years of continuous therapy, along with more common gastrointestinal side effects seen with oral formulations.
Because bisphosphonates bind persistently to bone, many clinicians consider periodic “drug holidays” after three to five years of IV therapy, an option not available with several of the newer biologic injections.
Which Osteoporosis Injections Reduce the Risk of Spine and Other Fractures Most Effectively?
When comparing injections purely on fracture-risk reduction, denosumab and romosozumab tend to lead. In the pivotal FREEDOM trial, denosumab reduced the risk of new spine fractures by 68% and hip fractures by 40% over three years compared with placebo.[1]
Romosozumab, a dual-acting sclerostin inhibitor, produced large gains in spine bone density and a 73% reduction in vertebral fracture risk at 12 months in placebo-controlled trial data.[6] As a dual-acting agent, it increases bone formation and decreases resorption. It carries a boxed warning about cardiovascular risk that limits its use in patients with a recent heart attack or stroke.[9]
Teriparatide has also been shown to reduce fracture risk at the spine.[7] Observational data from the European Forsteo Observational Study (EFOS) reported parallel reductions in back pain and improvements in function during teriparatide treatment, which many clinicians interpret as reflecting improved vertebral integrity and stability.[8]
These fracture-reduction differences track the broader antiresorptive vs. anabolic mechanism distinction between drug classes, which shapes how quickly a given injection can shift risk in patients with advanced disease and helps explain why the same trial evidence may support different first-line choices in different patients.
Comparing Cost and Accessibility of Osteoporosis Injection Options
Cost is often the deciding factor once efficacy and safety are comparable. Generic oral and IV bisphosphonates remain the most accessible option, often costing a fraction of biologic injections.
Denosumab (marketed as Prolia®) is typically billed per twice-yearly dose, while anabolic biologics carry substantially higher list prices. Romosozumab (Evenity®) was launched with a U.S. list price near $21,900 for a full 12-month, 12-dose course, and teriparatide (Forteo®) and abaloparatide (Tymlos®) can run in a similar range depending on formulation and insurance coverage.[5]
Costs and access also vary considerably outside the U.S., where several of these biologics are priced lower or reimbursed differently under national health systems. Regardless of which injection is chosen, calcium and vitamin D supplements are consistently recommended as a foundational, low-cost adjunct to any osteoporosis regimen, since adequate calcium and vitamin D intake supports the bone mineralization these drugs aim to preserve or rebuild.
What Is the Best Treatment Option for Osteoporosis?
There is no single answer to what is the most successful treatment for osteoporosis, since “success” depends on a patient’s baseline fracture risk, treatment history, and comorbidities. In general, current evidence favors starting anabolic agents such as teriparatide or romosozumab in patients at very high fracture risk, then transitioning to an antiresorptive agent such as denosumab or a bisphosphonate to maintain the bone density gained.[2]
For patients at moderate risk without a prior fracture, a bisphosphonate often remains a reasonable, cost-effective first step. In practice, the best treatment for osteoporosis in a given case is the treatment sequence individualized to that patient rather than any single injection used in isolation.
The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.
Citations
[1] Austin, Matthew et al. “Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.” Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research vol. 27,3 (2012): 687-93. doi:10.1002/jbmr.1472
[2] Mann, Russaal S et al. “A Comparison Between Bisphosphonates and Teriparatide in the Treatment of Postmenopausal Osteoporosis: A Systematic Review.” Cureus vol. 18,4 e106378. 3 Apr. 2026, doi:10.7759/cureus.106378
[3] Bone Health & Osteoporosis Foundation. “Raloxifene (Evista®).” Bone Health & Osteoporosis Foundation, www.bonehealthandosteoporosis.org/patients/treatment/medicationadherence/raloxifene-evista/.
[4] Royal Osteoporosis Society. “Raloxifene.” Royal Osteoporosis Society, theros.org.uk/information-and-support/treatments-and-medicines/a-to-z-list-of-medicines/raloxifene/.
[5] Keown, Alex. “Amgen Sets Annual List Price for Osteoporosis Drug Evenity at $21,900.” BioSpace, 16 Apr. 2019, www.biospace.com/amgen-sets-annual-list-price-for-osteoporosis-drug-evenity-at-21-900.
[6] Cosman, Felicia et al. “Romosozumab Treatment in Postmenopausal Women with Osteoporosis.” The New England journal of medicine vol. 375,16 (2016): 1532-1543. doi:10.1056/NEJMoa1607948
[7] Neer, R M et al. “Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.” The New England journal of medicine vol. 344,19 (2001): 1434-41. doi:10.1056/NEJM200105103441904
[8] Langdahl, Bente L et al. “Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS).” Calcified tissue international vol. 85,6 (2009): 484-93. doi:10.1007/s00223-009-9299-6
[9] Saag, Kenneth G et al. “Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.” The New England journal of medicine vol. 377,15 (2017): 1417-1427. doi:10.1056/NEJMoa1708322
This content was prepared and reviewed under our editorial guidelines , which govern how we source, verify, and update clinical and product information. Every claim is checked against peer-reviewed research, manufacturer documentation, or regulatory guidance before publication.
